Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc.
- Market cap
- $1.65B
Your view on AGIO
Overview
What the company does, where it operates, and who runs it.
About Agios Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Brian M. Goff
- Headquarters
- 88 Sidney Street, Cambridge, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Brian M. Goff
- Headquarters
- 88 Sidney Street, Cambridge, MA, US
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology.
The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.
Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Agios Pharmaceuticals, Inc.. Starting points for Agios Pharmaceuticals, Inc.: EPS -$6.25, beta 0.62 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Agios Pharmaceuticals, Inc.. Trailing twelve-month EPS for Agios Pharmaceuticals, Inc. stands at -$6.25. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Agios Pharmaceuticals, Inc.. Agios Pharmaceuticals, Inc. has reported as a listed company since 2013. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| TVGNTevogen Bio Holdings Inc. | Healthcare | NASDAQ | $24.6M | ||
| TVGNWTevogen Bio Holdings Inc. | Healthcare | NASDAQ | $5.6M | ||
| TVRDTvardi Therapeutics, Inc. | Healthcare | NASDAQ | $13.2M | ||
| TVTXTravere Therapeutics, Inc. | Healthcare | NASDAQ | $4.5B | ||
| TXTMProText Mobility, Inc. | Healthcare | OTC | $15.6M | ||
| TYRATyra Biosciences, Inc. | Healthcare | NASDAQ | $1.4B | ||
| UCBJFUCB S.A. | Healthcare | OTC | $58.4B | ||
| UCBJYUCB S.A. | Healthcare | OTC | $60.4B | ||
| UNCYUnicycive Therapeutics, Inc. | Healthcare | NASDAQ | $97.8M | ||
| UPBUpstream Bio, Inc. | Healthcare | NASDAQ | $87.2M | ||
| URGNUroGen Pharma Ltd. | Healthcare | NASDAQ | $1.4B | ||
| USRMU.S. Stem Cell, Inc. | Healthcare | OTC | $64,151 | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Agios Pharmaceuticals, Inc., and how their positions are changing. At a $1.65B market value, institutional positions materially move Agios Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Agios Pharmaceuticals, Inc. executives and directors. Shares of Agios Pharmaceuticals, Inc. have traded between $23.42 and $62.45 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Agios Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Agios Pharmaceuticals, Inc.. Coverage tracks Agios Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Agios Pharmaceuticals, Inc.